目的 觀察小牛血清去蛋白注射液聯(lián)合丁苯酞治療急性缺血性腦梗死的臨床效果。方法 選取2013年5月-2015年5月唐山康復(fù)醫(yī)療中心收治的急性缺血性腦梗死患者250例,隨機(jī)分為對照組和治療組,每組各125例。對照組靜脈滴注丁苯酞氯化鈉注射液,100 mL/次,2次/d,每次靜脈滴注時間大于50 min。治療組在對照組治療基礎(chǔ)上靜脈滴注小牛血清去蛋白注射液,20 mL溶于生理鹽水250 mL,1次/d。兩組均連續(xù)治療14 d。觀察兩組的臨床療效,同時比較兩組治療前后臨床神經(jīng)功能缺損程度(NDS)評分、超氧化物歧化酶(SOD)活性和丙二醛(MDA)的變化情況。結(jié)果 治療后,對照組和治療組的總有效率分別為69.6%、86.4%,兩組比較差異有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組患者NDS評分、MDA均顯著降低,SOD顯著升高,同組治療前后差異具有統(tǒng)計學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組,兩組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論 小牛血清去蛋白注射液聯(lián)合丁苯酞治療急性缺血性腦梗死臨床療效較好,能夠改善患者神經(jīng)功能缺損,安全性好,具有一定的臨床推廣應(yīng)用價值。

tients (88 cases) with endometrial carcinoma in the Lingao People's Hospital from April 2013 to August 2015 were divided into control and treatment group according to different treatment plans, and each group had 44 cases. All patients were given necessary basic treatment. The patients in the control group were po administered with Megestrol Acetate Tablets, 160 mg/time, once daily. The patients in the treatment group were iv administered with Compound Kushen Injection on the basis of the control group, 20 mL added into normal saline 250 mL, once daily. The patients in two groups were treated for 4 weeks. After treatment, short-term efficacies between two groups were compared, equally, the improvement of survival quality and adverse reactions were evaluated. Results After treatment, ORR and CBR in the control group were respectively 43.18% and 70.45%, equally, ORR and CBR in the treatment group were 65.91% and 88.64%, and there were differences between two groups (P < 0.05). After treatment, the improvement rate of survival quality in the control and treatment groups were 75.00% and 90.91%, respectively, and there were differences between two groups (P < 0.05). During the treatment, cases of adverse reactions in the control group were more than those in the treatment group, and the difference was statistically significant (P < 0.05). Conclusion Compound Kushen Injection combined with megestrol acetate has a good clinical efficacy in the treatment of endometrial carcinoma, and there are more adverse reactions in the control group than those in the treatment group, also can significantly improve the life quality, which has a certain clinical application value.